Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition) (DGU 2026) - Oct 15, 2026 - Abstract #V41-02; Pres time: Sep 18, 2026; 10:10 AM - 10:20 AM; Location: Room 28; P3 | "Combining 177 Lu-PSMA-617 with ADT + ARPI significantly improved rPFS in this first phase 3 trial of radioligand therapy in mHSPC. Safety findings were consistent with the known profile and QoL was not adversely affected. Copyright : Previously presented at the annual congress of the European Society for Medical Oncology (ESMO), FPN: LBA06, Scott T. Tagawa et al."
Clinical • Metastases • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • Xerostomia
|
|
O.A Sartor 1; J.M. Piulats 2; F. Saad 3; K. Fizazi 4; A.H. Reid 5; H. Beltran 6; G. Kramer 7; H. Mahammedi 8; M. Eiber 9; S. Gupta 10; D.E. Castellano Gauna 11; R.J. Hauke 12; H. Kim 13; C. Kwak 14; J.S.-T. Pang 15; E. Bouillaud 16; A. Zhang 17; O. Sakharova 17; M.J Morris 18
|